• Entertainment
  • Finance
  • Marketing
  • Real Estate
  • Technology
  • Social
National Journal Community Of e-Experts
Finance 0

Calithera Bioscience Shares Surge After Fast Track Designation Status

By Kurt Osterberg · On April 18, 2018

Calithera Biosciences, Inc. (NASDAQ: CALA)

Shares of Calithera Biosciences, Inc. gained $0.60, or $9.45% during premarket trade on Wednesday. The surge came after the company received a fast track designation status from the FDA for its CB-839 glutaminase inhibitor and cabozantinib, which are combined to treat kidney cancer, or renal cell carcinoma.

The biotech firm, which is based in California, said it is currently evaluating the treatment in a trial that involves about 298 kidney cancer patients, where the primary goal is for them to survive freely.

CALA Earnings & Outlook

Calithera Biosciences reported its quarterly earnings on March 8. The biotech firm announced earnings per share of 31 cents for the quarter, failing to beat the 22 cents consensus estimate of Thomson Reuters. Calithera had a negative return on equity of 17.48% and a negative net margin of 107.20%.

Revenue stood at $7.24 million, but analysts were expecting a figure of $7.28 million. The business posted earnings per share of 45 cents during the same quarter in the previous year. Wall Street forecasts that Calithera will post an EPS of $-1.21 for the current fiscal year.

This is right in my wheel house for penny stocks as it is a low floater priced under $10 per share so it will definitely be on my watch list!

Calithera Biosciences CEO Comments

The President and CEO of Calithera Biosciences made the following remarks after the U.S Food U.S. Food and Drug Administration granted it the Fast Track Designation: “Despite a number of new therapies for the treatment of renal cell carcinoma, there remains a significant unmet need among advanced patients who have received prior treatment. We are pleased that CB-839 has been granted Fast Track designation, demonstrating the FDA’s commitment to facilitate the development and expedite the review of our glutaminase inhibitor as an important new therapy for patients with advanced or metastatic renal cell carcinoma who have failed prior systemic therapy.”

Print Friendly, PDF & Email

Share Tweet

Kurt Osterberg

You Might Also Like

  • Finance

    Bored Ape Metaverse Launch Date set for April 30

  • Finance

    Celebrity Backed NFT Collections to Invest in 2022

  • Finance

    Bored Ape Metaverse Launch Date set for April 30

No Comments

Leave a reply Cancel reply

Top Finance

  • 3 Best Large-Cap Blend Mutual Funds For Enticing Returns 3 Best Large-Cap Blend Mutual Funds For Enticing Returns
  • Hedge Funds In The US Hedge Funds In The US
  • What is Value Chain Analysis? How to Deliver Value & Gain a Competitive Advantage What is Value Chain Analysis? How to Deliver Value & Gain a Competitive Advantage
  • 5 Ridiculously Useful Non-Monetary Reward Examples that Improve Employee Engagement 5 Ridiculously Useful Non-Monetary Reward Examples that Improve Employee Engagement
  • Chart: Amazon’s Dominance In Ecommerce Chart: Amazon’s Dominance In Ecommerce

New Posts

  • Bored Ape Metaverse Launch Date set for April 30

    Bored Ape Metaverse Launch Date set for April 30

    April 24, 2022
  • Celebrity Backed NFT Collections to Invest in 2022

    Celebrity Backed NFT Collections to Invest in 2022

    April 24, 2022
  • Bored Ape Metaverse Launch Date set for April 30

    Bored Ape Metaverse Launch Date set for April 30

    April 24, 2022
  • Mutant Ape Yacht Club Hits 32 ETH All Time High Price Floor

    Mutant Ape Yacht Club Hits 32 ETH All Time High Price Floor

    April 22, 2022
  • Rare CryptoPunk #7756 sells for $3.2 million (1050 ETH)

    Rare CryptoPunk #7756 sells for $3.2 million (1050 ETH)

    April 22, 2022
  • About
  • Contact Us
  • Privacy & Policy
  • Sitemap
  • Terms of use

Copyright © 2018-2021 NJCEE. All Rights Reserved.